CorNova Inc.
This article was originally published in Start Up
Executive Summary
Stent failure is a significant risk in endovascular procedures such as coronary angioplasty. The two primary causes of morbidity and mortality following stent placement are in-stent restenosis (scar tissue growing within the stent and clogging the artery) and in-stent thrombosis (clot formation within the stent, resulting in blockage of arterial blood flow). CorNova strives to treat or eliminate these two common stent complications by integrating innovative technologies into the procedures and devices that practitioners are already using. The company's flagship product, the FiberHalo stent delivery and angioplasty catheter, consists of tiny fiber optics that have been integrated into the catheter itself to measure the vessel from inside the balloon and detect final stent expansion., because stent under-expansion is the leading cause of stent failure.
You may also be interested in...
Start-Up Previews (04/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Stem Cell Therapies," features profiles of Amorcyte, California Stem Cell, Cardio3 BioSciences, CellDesign and Fate Therapeutics. Plus these Start-Ups Across Health Care: Alaxo, CorNova, PCI Biotech.
Start-Up Previews (04/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Stem Cell Therapies," features profiles of Amorcyte, California Stem Cell, Cardio3 BioSciences, CellDesign and Fate Therapeutics. Plus these Start-Ups Across Health Care: Alaxo, CorNova, PCI Biotech.
Volcano's Second Act
Launched in 2000, Volcano was a promising device start-up in what was seen at the time as one of the most exciting opportunities in cardiovascular medicine to come along in some time: vulnerable plaque. But the practical implications of vulnerable plaque have proved to be elusive, for both cardiologists and product companies. For one thing, while everyone agrees that vulnerable plaque is a fascinating concept, no one yet knows precisely what approach will work best, both in diagnosing the disease and treating it. . As the science of vulnerable plaque evolves, that evolution raises questions about the future relevance of a whole generation of tools to serve interventional cardiology. Thus, companies, like Volcano, that placed early bets on technology based on standard interventional cardiology tools, such as catheter- and guide wire-based devices, have had to hold somewhat contradictory thoughts in their mind at the same time: the benefits of conforming to existing approaches and methodologies in interventional cardiology and the likelihood that vulnerable plaque fundamentally changes certain basic assumptions of that specialty.